Clinical characteristics of the 415 patients with AML
| . | DNMT3Awild-type (n = 319) . | DNMT3Amutant (n = 96) . | DNMT3A R882 mutation (n = 58) . | DNMT3Amutant except for R882 codon (n = 38) . | P . |
|---|---|---|---|---|---|
| Sex, male, n (%) | 163 (51.10) | 47 (48.96) | 31 (53.45) | 16 (42.11) | .8 |
| Median age at study entry, y (range) | 41 (15-60) | 50.5 (18-60) | 51 (18-60) | 51 (18-60) | < .001* |
| Median WBC count at diagnosis, × 109/L (range) | 23.05 (0.6-274) | 52.9 (1.1-278) | 54.85 (2-278) | 48 (1.1-220) | < .001* |
| Median platelet count, × 109/L (range) | 50.5 (3-998) | 64 (10-494) | 64.5 (10-494) | 63.5 (10-267) | .003* |
| Median bone marrow blast, % (range) | 68 (0-98) | 68 (9-98) | 70 (9-97) | 65.5 (22-98) | .94* |
| FAB classification | .054† | ||||
| M0 | 15 (4.7) | 1 (1.0) | 1 (1.7) | 0 | .18† |
| M1 | 72 (22.6) | 15 (15.6) | 9 (15.5) | 6 (15.8) | .27† |
| M2 | 81 (25.4) | 23 (24.0) | 11 (19.0) | 12 (31.6) | .86† |
| M4 | 64 (20.1) | 15 (15.6) | 10 (17.2) | 5 (13.2) | .58† |
| M5 | 64 (20.1) | 36 (37.5) | 23 (39.7) | 13 (34.2) | < .001† |
| M6 | 5 (1.6) | 1 (1.0) | 0 | 1 (2.6) | ‡ |
| RAEB | 13 (4.0) | 3 (3.1) | 2 (3.4) | 1 (2.6) | .99† |
| ND | 5 (1.6) | 2 (2.1) | 2 (3.4) | 0 | ‡ |
| Cytogenetics | |||||
| Normal karyotype | 122 (38.2) | 72 (75.0) | 46 (79.3) | 26 (68.4) | < .001† |
| t(8;21) | 35 (11.9) | 0 | 0 | 0 | ‡ |
| inv(16) | 34 (10.6) | 0 | 0 | 0 | ‡ |
| del5/del5(q) | 13 (4.0) | 2 (2.0) | 1 (1.7) | 1 (2.6) | .65 |
| del7/del7q(q) | 24 (7.5) | 3 (3.1) | 2 (3.4) | 1 (2.6) | .78 |
| inv(3;3)/t(3;3) | 5 (1.5) | 0 | 0 | 0 | ‡ |
| Trisomy 8 | 27 (8.4) | 5 (5.2) | 3 (5.1) | 2 (5.2) | .39 |
| Trisomy 21 | 7 (2.1) | 0 | 0 | 0 | .86 |
| 11q23 | 25 (7.8) | 1 (1.0) | 0 | 1 (2.7) | .01 |
| Monosomy | 22 (6.9) | 2 (2.0) | 1 (1.7) | 1 (2.7) | .08 |
| Complex | 34 (10.6) | 4 (4.1) | 3 (5.1) | 1 (2.7) | .07 |
| Cytogenetic risk group | < .001† | ||||
| Favorable | 57 (17.9) | 0 | 0 | 0 | |
| Intermediate | 191 (59.9) | 85 (88.5) | 51 (88.0) | 34 (89.4) | |
| Adverse | 64 (20.0) | 6 (6.3) | 4 (6.9) | 2 (5.3) | |
| ND | 7 (2.2) | 5 (5.2) | 3 (5.1) | 2 (5.3) | |
| Molecular abnormalities | |||||
| FLT3ITD | 77 (24.1) | 39 (40.6) | 24 (41.3) | 15 (39.4) | .002 |
| FLT3TKD | 26 (8.2) | 15 (15.6) | 9 (15.5) | 6 (15.7) | .052 |
| NPM1 mutation | 60 (18.8) | 73 (76.0) | 46 (79.3) | 27 (71.0) | < .001 |
| CEBPASM | 7 (2.1) | 1 (1.0) | 1 (1.7) | 0 | .69† |
| CBPADM | 21 (6.5) | 2 (2.0) | 0 | 2 (5.2) | .15 |
| IDH1 mutation | 11 (3.4) | 22 (22.9) | 18 (31.0) | 4 (10.5) | < .001 |
| IDH2 mutation | 23 (7.2) | 13 (13.5) | 4 (6.9) | 9 (23.6) | .086 |
| cKit mutation | 22 (6.9) | 1 (1.0) | 1 (1.7) | 0 | ‡ |
| WT1 mutation | 21 (6.5) | 3 (3.1) | 1 (1.7) | 2 (5.2) | .311 |
| KRAS mutation | 1 (0.3) | 3 (3.1) | 2 (3.4) | 1 (2.6) | ‡ |
| NRAS mutation | 34 (10.6) | 8 (8.3) | 4 (6.9) | 4 (10.5) | .57 |
| EVI1 overexpression | 39 (12.2) | 1 (1.0) | 1 (1.7) | 0 | ‡ |
| . | DNMT3Awild-type (n = 319) . | DNMT3Amutant (n = 96) . | DNMT3A R882 mutation (n = 58) . | DNMT3Amutant except for R882 codon (n = 38) . | P . |
|---|---|---|---|---|---|
| Sex, male, n (%) | 163 (51.10) | 47 (48.96) | 31 (53.45) | 16 (42.11) | .8 |
| Median age at study entry, y (range) | 41 (15-60) | 50.5 (18-60) | 51 (18-60) | 51 (18-60) | < .001* |
| Median WBC count at diagnosis, × 109/L (range) | 23.05 (0.6-274) | 52.9 (1.1-278) | 54.85 (2-278) | 48 (1.1-220) | < .001* |
| Median platelet count, × 109/L (range) | 50.5 (3-998) | 64 (10-494) | 64.5 (10-494) | 63.5 (10-267) | .003* |
| Median bone marrow blast, % (range) | 68 (0-98) | 68 (9-98) | 70 (9-97) | 65.5 (22-98) | .94* |
| FAB classification | .054† | ||||
| M0 | 15 (4.7) | 1 (1.0) | 1 (1.7) | 0 | .18† |
| M1 | 72 (22.6) | 15 (15.6) | 9 (15.5) | 6 (15.8) | .27† |
| M2 | 81 (25.4) | 23 (24.0) | 11 (19.0) | 12 (31.6) | .86† |
| M4 | 64 (20.1) | 15 (15.6) | 10 (17.2) | 5 (13.2) | .58† |
| M5 | 64 (20.1) | 36 (37.5) | 23 (39.7) | 13 (34.2) | < .001† |
| M6 | 5 (1.6) | 1 (1.0) | 0 | 1 (2.6) | ‡ |
| RAEB | 13 (4.0) | 3 (3.1) | 2 (3.4) | 1 (2.6) | .99† |
| ND | 5 (1.6) | 2 (2.1) | 2 (3.4) | 0 | ‡ |
| Cytogenetics | |||||
| Normal karyotype | 122 (38.2) | 72 (75.0) | 46 (79.3) | 26 (68.4) | < .001† |
| t(8;21) | 35 (11.9) | 0 | 0 | 0 | ‡ |
| inv(16) | 34 (10.6) | 0 | 0 | 0 | ‡ |
| del5/del5(q) | 13 (4.0) | 2 (2.0) | 1 (1.7) | 1 (2.6) | .65 |
| del7/del7q(q) | 24 (7.5) | 3 (3.1) | 2 (3.4) | 1 (2.6) | .78 |
| inv(3;3)/t(3;3) | 5 (1.5) | 0 | 0 | 0 | ‡ |
| Trisomy 8 | 27 (8.4) | 5 (5.2) | 3 (5.1) | 2 (5.2) | .39 |
| Trisomy 21 | 7 (2.1) | 0 | 0 | 0 | .86 |
| 11q23 | 25 (7.8) | 1 (1.0) | 0 | 1 (2.7) | .01 |
| Monosomy | 22 (6.9) | 2 (2.0) | 1 (1.7) | 1 (2.7) | .08 |
| Complex | 34 (10.6) | 4 (4.1) | 3 (5.1) | 1 (2.7) | .07 |
| Cytogenetic risk group | < .001† | ||||
| Favorable | 57 (17.9) | 0 | 0 | 0 | |
| Intermediate | 191 (59.9) | 85 (88.5) | 51 (88.0) | 34 (89.4) | |
| Adverse | 64 (20.0) | 6 (6.3) | 4 (6.9) | 2 (5.3) | |
| ND | 7 (2.2) | 5 (5.2) | 3 (5.1) | 2 (5.3) | |
| Molecular abnormalities | |||||
| FLT3ITD | 77 (24.1) | 39 (40.6) | 24 (41.3) | 15 (39.4) | .002 |
| FLT3TKD | 26 (8.2) | 15 (15.6) | 9 (15.5) | 6 (15.7) | .052 |
| NPM1 mutation | 60 (18.8) | 73 (76.0) | 46 (79.3) | 27 (71.0) | < .001 |
| CEBPASM | 7 (2.1) | 1 (1.0) | 1 (1.7) | 0 | .69† |
| CBPADM | 21 (6.5) | 2 (2.0) | 0 | 2 (5.2) | .15 |
| IDH1 mutation | 11 (3.4) | 22 (22.9) | 18 (31.0) | 4 (10.5) | < .001 |
| IDH2 mutation | 23 (7.2) | 13 (13.5) | 4 (6.9) | 9 (23.6) | .086 |
| cKit mutation | 22 (6.9) | 1 (1.0) | 1 (1.7) | 0 | ‡ |
| WT1 mutation | 21 (6.5) | 3 (3.1) | 1 (1.7) | 2 (5.2) | .311 |
| KRAS mutation | 1 (0.3) | 3 (3.1) | 2 (3.4) | 1 (2.6) | ‡ |
| NRAS mutation | 34 (10.6) | 8 (8.3) | 4 (6.9) | 4 (10.5) | .57 |
| EVI1 overexpression | 39 (12.2) | 1 (1.0) | 1 (1.7) | 0 | ‡ |
P values not otherwise indicated were calculated with the 2-sided χ2 test and are for the comparisons between no DNMT3A mutations and any DNMT3A mutation. Cytogenetic risk group favorable includes t(8;21), inv(16) or t(15;17); adverse, inv(3)/t(3;3), t(6;9), 11q23 abnormalities other than t(9;11), del5, del5(q), del7, del7(q), t(9;22) or monosomal karyotypes (MK); and intermediate, the remaining AML cases.
WBC indicates white blood cell; FAB, French-American-British; RAEB, refractory anemia with excess blasts; and ND, not determined.
P values were calculated with Wilcoxon (Mann-Whitney) test for the comparisons between no DNMT3A mutations and any DNMT3A mutation.
P values were calculated with Fisher exact test for the comparisons between no DNMT3A mutations and any DNMT3A mutation.
Numbers were too low for reliable statistical analysis.